<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497766</url>
  </required_header>
  <id_info>
    <org_study_id>137/RC/KEMU</org_study_id>
    <nct_id>NCT04497766</nct_id>
  </id_info>
  <brief_title>Comparasion of Efficacy of Nebulized With Intravenous Magnesium Sulphate in Children With Asthma</brief_title>
  <official_title>Comparasion of Efficacy of Nebulized Magnesium Sulphate With Intravenous Magnesium Sulphate in Children With Acute Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saima Khatoon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Edward Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Edward Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study is to assess the effectiveness of nebulized magnesium sulphate in&#xD;
      children presenting with acute asthma.Study perfoma consists of demographic&#xD;
      variables,exclusion criteria and pediatric asthma score that includes respiratory rate,SPO2&#xD;
      at room air(requirement of oxygen),auscultatory findings in chest,dysnea and retractions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After getting informed consent from guardian,148 patients of acute moderate ro severe asthma&#xD;
      with pediatric asthma score 8-15 will be randomly classified into 2 groups and one group will&#xD;
      receive nebulization with magnesium sulphate and other will receive intravenous magnesium&#xD;
      sulphate and effectiveness will be compared by 4 point reduction in PAS from baseline in&#xD;
      either groups after 6 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of nebulized magnesium sulphate with intravenous magnesium sulphate in children with acute asthma will be assessed by a drop in PAS score, as assessed at 6 hours of intervention.</measure>
    <time_frame>6 hours</time_frame>
    <description>The intervention will be considered effective if there is a drop of at least 4 points in PAS score at hour-6 of intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of ICU stay</measure>
    <time_frame>72 hours/3 days</time_frame>
    <description>this will be measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospital stay</measure>
    <time_frame>120 hours/5 days</time_frame>
    <description>this will be measured in hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Asthma in Children</condition>
  <arm_group>
    <arm_group_label>Nebulized magnesium sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg of mgso4 in 20ml of normal saline via ultrasonic nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous magnesium sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium sulphate according to weight will be given intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Magnesium sulfate</intervention_name>
    <description>MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes</description>
    <arm_group_label>Nebulized magnesium sulphate</arm_group_label>
    <other_name>Nebulized MgSO4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous magnesium sulphate</intervention_name>
    <description>pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour</description>
    <arm_group_label>Intravenous magnesium sulphate</arm_group_label>
    <other_name>IV MgSO4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with age 2 to 12 years with acute moderate to severe exacerbation of asthma&#xD;
             as per operational definition children who are unrespoinsive to standard treatment of&#xD;
             asthma at 60 minutes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  those with history of chronic lung disease and abnormal renal function&#xD;
             contraindication for MgSO4 due to hepatic or renal disease allergy to MgSo4 children&#xD;
             who has other comorbid illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad-Haroon Hamid, MBBS,FCPS,FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>chairman /Head of department of pediatrics unit1 K.E medical university/mayo hospital l</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King edward medical university/mayo hospital lahore</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>56000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/24429155/</url>
    <description>Powell C, Dona RK, Lowe, J, Boland A, Petrou S, Doull I, et al. Magnesium sulphate in acute sever asthma in children (MAGNETIC): a randomized, placebo-controlled trial. The Lancet Respiratory Medicine. 2013;1(4):301-8.</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/25024668</url>
    <description>Kokotajlo S, Degnan L, Meyers R, Siu A, Robinson C. Use of intravenous magnesium sulfate for the treatment of an acute asthma exacerbation in pediatric patients.J Pediatr Pharmacol Ther. 2014;19(2) :91-7.</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/24429154/</url>
    <description>Goodacre S, Cohen J, Research Team. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial.Lancet Respir Med. 2013;1(4</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/25164315/</url>
    <description>Singhi S, Grover S, Bansal A, Chopra K. Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Peadiatrica. 2014;103(12):1301-6</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/23290189/</url>
    <description>Shan Z, Rong Y, Yang W, Wang D, Yao P, Xie J,et al. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. Respiratory medicine. 2013;107(3):321-30.</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/25652104/</url>
    <description>Alansari K, Ahmed W, Davidson B, Alamri M, Zakaria I, Alrifaari M. Nebulized magnesium for moderate and severe pediatric asthma: A randomized tria.Pediatr Pumonol 2015;50(12):1191-9.</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/24345031/</url>
    <description>Albuali WH. The Use of Intravenous and inhaled magnesium sulphate in management of children with bronchial asthma. J Matern Fetal Neonatal.2014;27(17):1809-15.</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/27996280/</url>
    <description>aengsuwan T, Watanatham S. A comparative pilot study of the efficacy and safety of nebulized magnesium sulfate and intravenous magnesium sulfate in children with severe acute asthma. Asian Pac/allergy immunol. 2016; 35(2):108-</description>
  </link>
  <reference>
    <citation>Powell C, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson P; MAGNETIC study group. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. Lancet Respir Med. 2013 Jun;1(4):301-8. doi: 10.1016/S2213-2600(13)70037-7. Epub 2013 Apr 22. Erratum in: Lancet Respir Med. 2013 Jun;1(4):285.</citation>
    <PMID>24429155</PMID>
  </reference>
  <reference>
    <citation>Kokotajlo S, Degnan L, Meyers R, Siu A, Robinson C. Use of intravenous magnesium sulfate for the treatment of an acute asthma exacerbation in pediatric patients. J Pediatr Pharmacol Ther. 2014 Apr;19(2):91-7. doi: 10.5863/1551-6776-19.2.91.</citation>
    <PMID>25024668</PMID>
  </reference>
  <reference>
    <citation>Goodacre S, Cohen J, Bradburn M, Gray A, Benger J, Coats T; 3Mg Research Team. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Jun;1(4):293-300. doi: 10.1016/S2213-2600(13)70070-5. Epub 2013 May 17.</citation>
    <PMID>24429154</PMID>
  </reference>
  <reference>
    <citation>Singhi S, Grover S, Bansal A, Chopra K. Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatr. 2014 Dec;103(12):1301-6. doi: 10.1111/apa.12780. Epub 2014 Oct 2.</citation>
    <PMID>25164315</PMID>
  </reference>
  <reference>
    <citation>Shan Z, Rong Y, Yang W, Wang D, Yao P, Xie J, Liu L. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. Respir Med. 2013 Mar;107(3):321-30. doi: 10.1016/j.rmed.2012.12.001. Epub 2013 Jan 3. Review.</citation>
    <PMID>23290189</PMID>
  </reference>
  <reference>
    <citation>Alansari K, Ahmed W, Davidson BL, Alamri M, Zakaria I, Alrifaai M. Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial. Pediatr Pulmonol. 2015 Dec;50(12):1191-9. doi: 10.1002/ppul.23158. Epub 2015 Feb 4.</citation>
    <PMID>25652104</PMID>
  </reference>
  <reference>
    <citation>Albuali WH. The use of intravenous and inhaled magnesium sulphate in management of children with bronchial asthma. J Matern Fetal Neonatal Med. 2014 Nov;27(17):1809-15. doi: 10.3109/14767058.2013.876620. Epub 2014 Jan 30. Review.</citation>
    <PMID>24345031</PMID>
  </reference>
  <reference>
    <citation>Daengsuwan T, Watanatham S. A comparative pilot study of the efficacy and safety of nebulized magnesium sulfate and intravenous magnesium sulfate in children with severe acute asthma. Asian Pac J Allergy Immunol. 2017 Jun;35(2):108-112. doi: 10.12932/AP0780.</citation>
    <PMID>27996280</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>King Edward Medical University</investigator_affiliation>
    <investigator_full_name>Saima Khatoon</investigator_full_name>
    <investigator_title>Post Graduate Resident in Pediatrics (MD Paeds)</investigator_title>
  </responsible_party>
  <keyword>asthma in children</keyword>
  <keyword>intravenous magnesium sulphate</keyword>
  <keyword>nebulized magnesium sulphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be shared after publication on a reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

